Año 2025 / Volumen 117 / Número 12
Original
Fluoxetine in functional constipation with somatic symptom disorder ‒ Efficacy and safety from a propensity score-matched cohort study

737-744

DOI: 10.17235/reed.2025.11434/2025

Bin Yang, Xiangying Feng, Qinxian Huang, Xuzhao Li, Xue Jiang, Weihong Fu, Qingchuan Zhao, Zhifeng Zhao,

Resumen
Introduction: functional constipation (FC) is often accompanied by somatic symptom disorder (SSD), especially in refractory conditions. In such patients, constipation manifestations often appear to reflect heightened somatic symptoms rather than bowel dysfunction such as excessive preoccupation to defecation. Therefore, we conducted a cohort study to evaluate the efficacy and safety of fluoxetine in patients with FC and comorbid SSD. Methods: the cohort study involved 316 FC patients with somatic symptoms. Among them, 161 patients received fluoxetine, while 155 were treated with polyethylene glycol (PEG). Using propensity scores, patients were matched into 77 pairs for comparative analysis. The primary outcome was the proportion who achieved ≥ 3 completely spontaneous bowel movements (CSBMs) per week at six-months. Secondary outcomes included the assessment of bowel symptom, mental scale, and treatment satisfaction. Safety was evaluated by adverse events. Results: at six months, 40.26 % of the fluoxetine group achieved the primary endpoint compared to 22.08 % in the PEG group (p = 0.009). Significant improvements were noted in secondary outcomes, including frequency of CSBMs, bowel symptom severity, GAD-9 score, and patient satisfaction. Key factors contributing to treatment effectiveness included baseline GAD-9 scores > 9 (OR = 5.01; p < 0.01). Adverse events occurred in 16 cases (9.9 %) of the fluoxetine group, with most being mild life-affecting. Conclusion: fluoxetine appears to be a safe and effective therapeutic option over a six-month period for patients with FC and SSD, exerting dual benefits in alleviating both constipation and associated psychological symptoms.
Resumen coloquial
A substantial proportion of patients with functional constipation (FC) experience both difficulty in defecation and marked anxiety and preoccupation with bowel habits, features characteristic of somatic symptom disorder (SSD). In this cohort, fluoxetine, an established SSD therapy, achieved significantly greater clinical improvement than the standard laxative polyethylene glycol (PEG) and was associated with a favorable safety profile.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Instrucciones para citar
Yang B, Feng X, Huang Q, Li X, Jiang X, Fu W, et all. Fluoxetine in functional constipation with somatic symptom disorder ‒ Efficacy and safety from a propensity score-matched cohort study. 11434/2025


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1200 veces.
Este artículo ha sido descargado 86 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 25/06/2025

Aceptado: 09/07/2025

Prepublicado: 30/07/2025

Publicado: 12/12/2025

Tiempo de prepublicación: 35 días

Tiempo de edición del artículo: 170 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2026 y Creative Commons. Revista Española de Enfermedades Digestivas